These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17917441)

  • 41. Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits.
    Park SC; Yun HI; Oh TK
    J Vet Med Sci; 1998 May; 60(5):661-3. PubMed ID: 9637308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves.
    Gips M; Soback S
    J Vet Pharmacol Ther; 1996 Apr; 19(2):130-4. PubMed ID: 8735421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses.
    Park SC; Yun HI
    Res Vet Sci; 2003 Feb; 74(1):79-83. PubMed ID: 12507569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determination of bioequivalence of lomefloxacin tablets using urinary excretion data.
    Shah SA; Rathod IS; Savale SS; Patel DB
    J Pharm Biomed Anal; 2002 Nov; 30(4):1319-29. PubMed ID: 12408922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Norfloxacin concentrations in seminal plasma measured by HPLC.
    Bologna M; Vaggi L; Flammini D; Carlucci G; Francavilla F
    Drugs Exp Clin Res; 1985; 11(11):801-4. PubMed ID: 3836861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine.
    Ilupeju TO; Oladeinde FO; Olaniyi AA; Amosu MA
    Afr J Med Med Sci; 2004 Dec; 33(4):341-5. PubMed ID: 15977442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Consequences of diarrhoeal disease on the pharmacokinetics of norfloxacin.
    Bergan T; Lolekha S; Cheong MK; Poh CL; Patancharoen S
    Scand J Infect Dis Suppl; 1988; 56():11-3. PubMed ID: 3249925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients.
    Moreau JL; Royer-Morrot MJ; Lozniewski A; Trackoen G; Delavault P; Royer RJ
    Eur J Clin Pharmacol; 1996; 49(5):401-5. PubMed ID: 8866637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of norfloxacin absorption by antacids.
    Nix DE; Wilton JH; Ronald B; Distlerath L; Williams VC; Norman A
    Antimicrob Agents Chemother; 1990 Mar; 34(3):432-5. PubMed ID: 2334155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly.
    Kelly JG; Deaney NB; Lavan J; Noel J
    Br J Clin Pharmacol; 1988 Dec; 26(6):787-90. PubMed ID: 3242584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep.
    González F; San Andrés MI; Nieto J; San Andrés MD; Waxman S; Vicente ML; Lucas JJ; Rodríguez C
    J Vet Pharmacol Ther; 2001 Aug; 24(4):241-5. PubMed ID: 11555178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sucralfate reduces the gastrointestinal absorption of norfloxacin.
    Parpia SH; Nix DE; Hejmanowski LG; Goldstein HR; Wilton JH; Schentag JJ
    Antimicrob Agents Chemother; 1989 Jan; 33(1):99-102. PubMed ID: 2712548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An approach to select the appropriate statistical method for testing bioequivalence.
    Steyn HS; Koeleman HA; Gouws E; Ritschel WA
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):156-60. PubMed ID: 1822089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative bioavailability of two oral formulations of ciprofloxacin.
    Trejo D; Toledo A; Carrasco-Portugal Mdel C; Aguilar-Cota ME; Herrera JE; Flores-Murrieta FJ
    Proc West Pharmacol Soc; 2003; 46():134-5. PubMed ID: 14699910
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of simulated microgravity on the disposition and tissue penetration of ciprofloxacin in healthy volunteers.
    Schuck EL; Grant M; Derendorf H
    J Clin Pharmacol; 2005 Jul; 45(7):822-31. PubMed ID: 15951472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers.
    van Crevel R; Nelwan RH; Borst F; Sahiratmadja E; Cox J; van der Meij W; de Graaff M; Alisjahbana B; de Lange WC; Burger D
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):500-3. PubMed ID: 15141745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacokinetics of pefloxacin in burn patients].
    Potel G; Meignier M; Touzé MD; Montay G; Drugeon HB; Baron D
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):777-80. PubMed ID: 3309814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diosmin pretreatment affects bioavailability of metronidazole.
    Rajnarayana K; Reddy MS; Krishna DR
    Eur J Clin Pharmacol; 2003 Apr; 58(12):803-7. PubMed ID: 12698306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative bioavailability of two furosemide formulations in humans.
    Martin BK; Uihlein M; Ings RM; Stevens LA; McEwen J
    J Pharm Sci; 1984 Apr; 73(4):437-41. PubMed ID: 6726624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers.
    Persiani S; Sassolas G; Piscitelli G; Bizollon CA; Poggesi I; Pianezzola E; Edwards DM; Strolin Benedetti M
    J Pharm Sci; 1994 Oct; 83(10):1421-4. PubMed ID: 7884663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.